Duyuru • Aug 21
BioSyent Inc. Declares Third Quarter 2026 Dividend, Payable on September 15, 2026 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. This third quarter 2026 dividend compares to a second quarter dividend of CAD 0.055 per common share. Duyuru • Aug 14
BioSyent Inc. to Report Q2, 2026 Results on Aug 20, 2026 BioSyent Inc. announced that they will report Q2, 2026 results After-Market on Aug 20, 2026 Duyuru • May 21
BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution) BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses. Duyuru • May 16
BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share. Duyuru • May 08
BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026 BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026 Duyuru • Mar 13
BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026 BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026 Duyuru • Mar 03
BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million. BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million.
For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million.
Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026.
Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.
BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million. Duyuru • Feb 17
BioSyent Inc., Annual General Meeting, May 14, 2026 BioSyent Inc., Annual General Meeting, May 14, 2026. Duyuru • Feb 09
BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million. BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million.
For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million.
Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026.
Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. Duyuru • Jan 30
BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share. Duyuru • Nov 22
BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share. Duyuru • Nov 14
BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025 BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025 Duyuru • Aug 22
BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share. Duyuru • Aug 15
BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025 BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025 Duyuru • May 16
BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • May 09
BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025 BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025 Duyuru • Mar 07
BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025 BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025 Duyuru • Mar 05
BioSyent Inc., Annual General Meeting, May 15, 2025 BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canada Duyuru • Jan 31
BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share. Duyuru • Nov 20
December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • Nov 14
BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024 BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024 Duyuru • Aug 27
Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024 BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share. Duyuru • May 18
BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share. Duyuru • May 11
BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024 BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024 Duyuru • Mar 19
BioSyent Inc., Annual General Meeting, May 16, 2024 BioSyent Inc., Annual General Meeting, May 16, 2024. Duyuru • Mar 07
BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024 BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024 Duyuru • Feb 07
BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share. Duyuru • Nov 17
BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share. Duyuru • Nov 10
BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023 BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023 Duyuru • Aug 23
BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share. Duyuru • Aug 16
BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023 BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023 Duyuru • May 26
BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • May 19
BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023 BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023 Duyuru • Feb 02
BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share. 
